Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 299 participants.

Also called NCT02458287

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 299 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02458287
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02458287. Randomized; quadruple masking; primary purpose treatment. Start 2015-06 (actual); primary completion 2016-02 (actual). Results posted on 2017-12-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
Acronym
SPIRE-AI
Condition
Hyperlipidemia
Intervention (Biological)
Bococizumab 150mg
Intervention (Biological)
Bococizumab 75mg
Intervention (Biological)
Bococizumab 150mg placebo
Intervention (Biological)
Bococizumab 75mg placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct02458287
Content hash
07540e13ca2aff6c73545b0d70287a4de0775685cbd9718db2457fd0a7e66ee4